Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
- PMID:22296306
- DOI: 10.3109/09513590.2011.650660
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Abstract
Polycystic ovary syndrome (PCOS) affects 5%-10% of women in reproductive age, and it is the most common cause of infertility due to ovarian dysfunction and menstrual irregularity. Several studies have reported that insulin resistance is common in PCOS women, regardless of the body mass index. The importance of insulin resistance in PCOS is also suggested by the fact that insulin-sensitizing compounds have been proposed as putative treatments to solve the hyperinsulinemia-induced dysfunction of ovarian response to endogenous gonadotropins. Rescuing the ovarian response to endogenous gonadotropins reduces hyperandrogenemia and re-establishes menstrual cyclicity and ovulation, increasing the chance of a spontaneous pregnancy. Among the insulin-sensitizing compounds, there is myo-inosiol (MYO). Previous studies have demonstrated that MYO is capable of restoring spontaneous ovarian activity, and consequently fertility, in most patients with PCOS. With the present review, we aim to provide an overview on the clinical outcomes of the MYO use as a treatment to improve ovarian function and metabolic and hormonal parameters in women with PCOS.
Similar articles
- Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.Pizzo A, Laganà AS, Barbaro L.Pizzo A, et al.Gynecol Endocrinol. 2014 Mar;30(3):205-8. doi: 10.3109/09513590.2013.860120. Epub 2013 Dec 19.Gynecol Endocrinol. 2014.PMID:24351072Clinical Trial.
- Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, Artini PG.Genazzani AD, et al.Gynecol Endocrinol. 2012 Dec;28(12):969-73. doi: 10.3109/09513590.2012.685205. Epub 2012 May 21.Gynecol Endocrinol. 2012.PMID:22612517Clinical Trial.
- Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A.Papaleo E, et al.Gynecol Endocrinol. 2007 Dec;23(12):700-3. doi: 10.1080/09513590701672405. Epub 2007 Oct 10.Gynecol Endocrinol. 2007.PMID:17952759Clinical Trial.
- Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature.Regidor PA, Schindler AE, Lesoine B, Druckman R.Regidor PA, et al.Horm Mol Biol Clin Investig. 2018 Mar 2;34(2):/j/hmbci.2018.34.issue-2/hmbci-2017-0067/hmbci-2017-0067.xml. doi: 10.1515/hmbci-2017-0067.Horm Mol Biol Clin Investig. 2018.PMID:29498933Review.
- [The role of inositol deficiency in the etiology of polycystic ovary syndrome disorders].Jakimiuk AJ, Szamatowicz J.Jakimiuk AJ, et al.Ginekol Pol. 2014 Jan;85(1):54-7. doi: 10.17772/gp/1691.Ginekol Pol. 2014.PMID:24505965Review.Polish.
Cited by
- A Potential Therapeutic Role of Myoinositol in the Metabolic and Cardiovascular Profile of PCOS Iranian Women Aged between 30 and 40 Years.Salehpour S, Nazari L, Hoseini S, Saharkhiz N, Ghazi F, Sohrabi MR.Salehpour S, et al.Int J Endocrinol. 2016;2016:7493147. doi: 10.1155/2016/7493147. Epub 2016 Aug 25.Int J Endocrinol. 2016.PMID:27648072Free PMC article.
- The Study of Myo-Inositol's Anxiolytic Activity on Zebrafish (Danio rerio).Derkaczew M, Kędziora B, Potoczna M, Podlasz P, Wąsowicz K, Jóźwik M, Wojtkiewicz J.Derkaczew M, et al.Nutrients. 2024 Jun 23;16(13):1997. doi: 10.3390/nu16131997.Nutrients. 2024.PMID:38999746Free PMC article.
- Altered Ovarian Inositol Ratios May Account for Pathological Steroidogenesis in PCOS.Unfer V, Dinicola S, Laganà AS, Bizzarri M.Unfer V, et al.Int J Mol Sci. 2020 Sep 28;21(19):7157. doi: 10.3390/ijms21197157.Int J Mol Sci. 2020.PMID:32998310Free PMC article.Review.
- Clinical and Metabolic Effects of Alpha-Lipoic Acid Associated with Two Different Doses of Myo-Inositol in Women with Polycystic Ovary Syndrome.Fruzzetti F, Benelli E, Fidecicchi T, Tonacchera M.Fruzzetti F, et al.Int J Endocrinol. 2020 Mar 19;2020:2901393. doi: 10.1155/2020/2901393. eCollection 2020.Int J Endocrinol. 2020.PMID:32256570Free PMC article.
- Effects of L-carnitine on Polycystic Ovary Syndrome.Salehpour S, Nazari L, Hoseini S, Moghaddam PB, Gachkar L.Salehpour S, et al.JBRA Assist Reprod. 2019 Oct 14;23(4):392-395. doi: 10.5935/1518-0557.20190033.JBRA Assist Reprod. 2019.PMID:31294953Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical